Are the prescriptions you’re taking right now erasing your memory?‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎



<[link removed]>

October 11


 



These 9 Prescription Drugs Erase Memory

See the List →
<[link removed]>






Are the prescriptions you’re taking right now erasing your memory?

Doctors confirm that 9 common prescription drugs
<[link removed]>
cause brain damage and Alzheimer’s diagnoses — not aging.
Many people never realize what’s happening until it’s too late.

If you’re over 50 and take even one of these medications, your brain is
already at risk.
<[link removed]>


<[link removed]>
More than1,429,000 American seniors are affected every year.
See the list of drugs before the damage is permanent.
<[link removed]>


If you'd rather not receive these emails, you can unsubscribe here
<[link removed]>
.


 





Health Briefing · The Hill Report
Alzheimer's Pathology Can Now Be Measured in a Blood Draw
Four blood tests cleared since May 2025 estimate whether the brain carries
Alzheimer's proteins, and the guidelines place them inside an evaluation that
also looks for every other contributing cause, medicines included. Connor Hill
· InsightfulWord · October 11
Key points

Sudden severe confusion can be delirium, a rapid change in brain function that
certain medicines, including pain medicines, sedatives and anticholinergic
drugs, can trigger. Sudden confusion with trouble speaking, one-sided weakness
or a severe headache means calling9-1-1.

The Food and Drug Administration has cleared four blood tests for Alzheimer's
pathology sinceMay 2025. In the agency's review of the first, 91.7% of positive
results and97.3% of negative results matched brain scans or spinal fluid.

The Alzheimer's Association's blood-test guideline sets above 90% sensitivity
for any such test, withabove 90% specificity required before a result can
confirm rather than triage.

The association's diagnostic guideline lists "use of cognitively impairing
medications" among the contributing conditions an evaluation must identify.
Every cleared blood test is labeled as not a stand-alone diagnosis.
A memory complaint after 50 has several possible sources, and a careful
evaluation looks for all of them at once. Medicines are on that list in the
professional guidance, alongside thyroid disease, vitamin deficiency,
depression, strokes and other brain diseases.

What has changed in the past 18 months is how the Alzheimer's part of the
question is answered. Confirming it used to require a brain scan or a spinal
tap. It can now begin with a blood sample, under rules that say exactly when
the result counts.

On the tape
Oct 8A newspaper report described a $26 million National Institutes of Health
study, led from Pennsylvania, that will follow 330 carriers of a gene variant
over five years at 14 sites to find early markers of frontotemporal dementia
and ALS.Why it matters: frontotemporal dementia is one of the conditions a
memory evaluation separates from Alzheimer's, and the study's purpose is
markers that flag it before symptoms.
Oct 7Trade coverage described a Lancet Neurology study of 197 patients treated
with an anti-amyloid drug, in which 34 of 130 blood proteins changed with the
number of infusions, some in unexpected directions.Why it matters: the lead
author said clinicians "should not automatically interpret these unexpected
biomarker changes as a reason for alarm," a reminder that markers behave
differently once treatment begins.
Oct 7A geriatric psychiatrist told a clinical publication that serious kidney
failure is the most frequent confounder of Alzheimer's blood tests, producing
false positives mainly for the pTau217 marker, and named morbid obesity as
another.Why it matters: a blood result is read against the person's other
conditions, not on its own.
Oct 3The same specialist said in an earlier interview that the tests are
recommended only for people with objective cognitive impairment, after thyroid
blood work, depression screening and brain imaging.Why it matters: in his
description the blood test comes after the basic workup, not before it.
Oct 8A check of the Food and Drug Administration's press announcements from
September 30 to October 8 found none on Alzheimer's tests or drugs.Why it
matters: the most recent clearances located for this briefing were announced on
August 21 and August 24.
Before anything else
The National Library of Medicine describes delirium as "sudden severe
confusion due to rapid changes in brain function," lists certain pain
medicines, sedatives and anticholinergic medicines among its triggers, and
advises contacting a provider for any rapid change in mental status. The
Centers for Disease Control and Prevention lists sudden confusion, trouble
speaking, numbness or weakness on one side, trouble seeing or walking, and a
sudden severe headache as stroke signs, and says to call 9-1-1 right away and
note when symptoms began. Memory problems that persist for a few weeks are a
reason to see a doctor. No prescribed medication should be started, stopped or
changed except with the prescriber.


What the Diagnosis Now Rests On
In June 2024 an Alzheimer's Association workgroup published revised criteria
that define the disease biologically. Alzheimer's is "a biological process that
begins with the appearance of Alzheimer's-related changes" in the brain; memory
loss and other symptoms come later, and because other disorders produce similar
symptoms, the clinical picture alone is not treated as diagnostic.

The criteria name "Core 1" biomarkers, which directly reflect amyloid plaques
or a modified form of the tau protein. They include amyloid PET scans, several
spinal fluid ratios and "accurate" blood assays such as pTau217. An abnormal
Core 1 result is enough to establish the biological diagnosis.

Two limits come with that. The workgroup says biomarkers are currently
intended for people with symptoms, and recommends against diagnostic testing in
cognitively unimpaired people outside research. And the biological diagnosis is
"meant to assist rather than supplant the clinical evaluation."

That distinction matters for reading any result. A positive marker shows that
Alzheimer's pathology is present. It is an association between protein and
disease process, and it does not by itself establish that the pathology
accounts for every symptom a person has, or exclude other conditions that
coexist with it.

By the numbers
4Blood tests for Alzheimer's pathology cleared by the agency since May 2025
499Plasma samples in the agency's review of the first cleared test
91.7%Share of that test's positive results confirmed by PET or spinal fluid
97.3%Share of its negative results confirmed negative
Under 20%Patients who received an indeterminate result in that review
1,142Adults with cognitive symptoms in the validation of the test cleared from
age 40

What the Blood Tests Measure
The first clearance came on May 16, 2025. That test measures two proteins in
plasma, pTau217 and beta-amyloid 1-42, and reports their ratio, which tracks
the presence or absence of amyloid plaques. It is for adults 55 and older with
signs and symptoms, in specialized care settings. The agency warned that false
positives could lead to an inappropriate diagnosis and unnecessary treatment,
and false negatives to delayed care.

A second test, cleared in October 2025, measures a different marker, pTau181,
and was the first cleared for primary care, as a rule-out test; its negative
predictive value was 97.9% in a 312-person study. A third, announced August 21,
2026, combines amyloid and tau ratios into a score from 0 to 100 and is the
first cleared from age 40, with positive and negative predictive values of
97.6% and 93.1%. A fourth, announced August 24, uses pTau217 alone and reports
positive, intermediate or negative results.

Every one is labeled for people with cognitive symptoms and as an aid, not a
stand-alone diagnosis. The association's 2025 guideline sets the bar. A triage
test needs above 90% sensitivity and above 75% specificity; its negatives rule
out Alzheimer's pathology, but positives need PET or spinal fluid confirmation.
A confirmatory test needs above 90% on both.

🧪 Lab SignalAbove 90%
The sensitivity and specificity the Alzheimer's Association guideline requires
before a blood test can confirm Alzheimer's pathology on its own in specialty
care. A test meeting only the triage standard, above 90% sensitivity and above
75% specificity, can rule the pathology out, but its positive results still go
to a PET scan or spinal fluid analysis.


How Other Causes Are Separated
The association's 2024 diagnostic guideline, with 19 recommendations, sets a
three-step order. First establish how well the person is functioning. Then
characterize the pattern of symptoms. Only then narrow the list of brain
diseases or conditions that could be causing them.

The second half of that process is where other causes are examined. Routine
first-tier laboratory tests for all patients include thyroid-stimulating
hormone, vitamin B12, homocysteine, a blood count and a metabolic panel.
Structural brain imaging, MRI or CT, is recommended to look for strokes, tumors
and other causes. The guideline lists "use of cognitively impairing
medications" among potentially contributing conditions, and describes
specialists using detailed assessment to "disentangle the adverse effects of
prior or current treatments" from disease symptoms.

Biomarkers come in for symptomatic patients in whom Alzheimer's is part of the
differential. Spinal fluid and amyloid PET are advised where uncertainty
remains. The guideline's language of contributing conditions allows for
overlap: a person can have Alzheimer's pathology and a medication effect at the
same time, which is why the medication review and the biomarker test sit in the
same evaluation rather than replacing one another.

Where the tests are defined
Food and Drug Administration, May 16, 2025First blood test cleared, pTau217 to
beta-amyloid 1-42 ratioAdults 55 and older, specialized care
Clearance, October 2025pTau181 rule-out test for primary care97.9% negative
predictive value, 312 participants
Clearance announced August 21, 2026Combined amyloid and tau probability score
Symptomatic adults 40 and older
Clearance announced August 24, 2026Single-marker pTau217 test, rule-in and
rule-outAdults 55 and older, primary and specialty care
One question for the desk
When memory came up at a recent appointment, was the full medication list
reviewed in the same visit as any blood test or scan?

Hit reply — one line is enough.

Worth stating plainly
Alzheimer's pathology can now be estimated from a blood sample, using one of
four cleared tests, each intended for people with symptoms and none a
stand-alone diagnosis. Professional guidelines place the test inside an
evaluation that also reviews medicines, laboratory results and brain imaging,
because several causes can act together. Sudden confusion or stroke signs need
emergency care, and medication changes belong with the prescriber.

The short checklist
1.Call 9-1-1 for sudden confusion with trouble speaking, one-sided weakness or
a severe headache.
2.Raise memory changes that persist for a few weeks with a doctor.
3.Bring a complete list of prescription and nonprescription medicines, and
review it with the prescriber.
4.Ask whether thyroid, vitamin B12 and other first-tier tests and brain
imaging have been done.
5.Ask whether a blood test was used to triage or to confirm, and what an
intermediate result means.
6.Mention kidney disease or significant obesity when any blood result is
discussed.


Replies to this briefing reach a person, not a queue.

Connor Hill reads every reply.

Sources checked Verified October 08, 2026 Food and Drug Administration, FDA
Clears First Blood Test Used in Diagnosing Alzheimer's Disease, May 16, 2025,
and press announcements index checked through October 8, 2026 Alzheimer's
Association, Revised Criteria for Diagnosis and Staging of Alzheimer's Disease,
June 27, 2024, and Clinical Practice Guideline on Blood-Based Biomarkers in
Specialty Care, 2025 Dickerson, Atri and colleagues, Alzheimer's Association
DETeCD-ADRD clinical practice guideline, Alzheimer's and Dementia, 2024
NeurologyLive, pTau181 clearance report, October 14, 2025, and lecanemab plasma
biomarker study report, October 7, 2026; Healio, August 21, 2026, and Medical
News Today on the 2026 clearances Psychiatric Times interviews with George
Grossberg, October 3 and October 7, 2026; The Spokesman-Review, NIH-funded
frontotemporal dementia study, October 8, 2026 National Library of Medicine,
MedlinePlus, Delirium; Centers for Disease Control and Prevention, Signs and
Symptoms of Stroke; National Institute on Aging, Memory Problems,
Forgetfulness, and Aging Connor Hill writes The Hill Report for InsightfulWord,
a daily briefing on the machinery behind the numbers.



Insightful Word (IW) is a daily publication of TerraTrance Technologies, LLC.



We'd love to hear from you. Reply to this email with any question, or write to
us [email protected] <mailto:[email protected]>



TerraTrance Technologies, LLC. This email may not be reproduced or distributed
without prior written consent.

200 Broadway Blvd NE, Albuquerque, NM 87102

Privacy Policy <[link removed]>
Terms & Conditions <[link removed]>
Unsubscribe
<[link removed]>



© 2026 Insightful Word (IW) · Thank you for reading.